about
DNA-damage-responsive acetylation of pRb regulates binding to E2F-1Biosimilars: Extrapolation for oncologyDynamic and influential interaction of cancer cells with normal epithelial cells in 3D culture.Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancerValidation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancerAntibody-based proteomics: fast-tracking molecular diagnostics in oncology.miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro.Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancerTumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifenA novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer.FKBPL: a marker of good prognosis in breast cancer.Breast cancer proteomics: clinical perspectives.Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitromiRNA dysregulation in breast cancer.microRNAs: a new class of breast cancer biomarkers.p53 as a target for the treatment of cancer.Vitamin D receptor as a target for breast cancer therapy.Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways.The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancer.De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancerAltered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.Fam60a defines a variant Sin3a-Hdac complex in embryonic stem cells required for self-renewal.A high degree of chromosomal instability at 13q14 in cutaneous squamous cell carcinomas: indication for a role of a tumour suppressor gene other than Rb.Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.Altered p53 expression in benign and malignant skin lesions from renal transplant recipients and immunocompetent patients with skin cancer: correlation with human papillomaviruses?Surface-induced changes in protein adsorption and implications for cellular phenotypic responses to surface interaction.Dysregulated mitogen-activated protein kinase signalling as an oncogenic basis for clear cell sarcoma of the kidney.Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1β secretion and insulin resistance despite obesity.BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer.Molecular basis of cell–biomaterial interaction: Insights gained from transcriptomic and proteomic studiesCopy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapyErratum: Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitroLoss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With BevacizumabEpigenome-wide SRC-1–Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast CancerMaternal and fetal cocaine- and amphetamine-regulated transcript in diabetic and non-diabetic pregnancy
P50
Q24299739-698F5E03-4707-494C-8639-101DF68A5242Q26746241-2CF4BFF4-65A2-4EE5-A286-407FCF80E4D2Q30596963-1503D5B9-B2A2-45C2-AEE5-498E486356C7Q31034941-C5521D79-463E-46C9-9B59-EB301F7B6CB5Q33548538-DA065346-B56A-4004-B2CD-6D515146DD14Q33752148-9C7735EE-38E7-4B59-9BCE-4741D5C03DD2Q34132010-B83B713B-DC19-4ED5-8435-3D483557EFC5Q34305636-8D5B84FE-49B4-4D9D-AF78-25D46975F73CQ34485296-FF4147DE-FC11-4DB1-93CA-87E37110330AQ35029556-8C6D25A0-B7E8-4728-8CA2-C21E1D82DFD1Q35599434-0136D2F3-9432-4FB9-84D1-4D32B8D7BB8DQ35828542-BBD72D3A-8CD9-4F40-9D96-C87D840E50D7Q36717346-05BA64E6-E61E-4762-8C9E-8D85218D972FQ37457681-B9E6E4D0-B866-48D7-B532-C548F31C952FQ38160824-A2FB7D07-594D-447D-BC3E-648810BF0627Q38197675-A50864B3-72DF-4EE2-99F6-59370CDF0722Q38279586-3719690F-D9CE-4D58-8D5E-F565D4377A72Q38436824-740DA293-E12C-43D2-A6F6-0272B3DED404Q38741165-EF666DA1-2DDE-4055-81B5-E9F90A31DDA6Q38746991-6B0549A5-B221-4734-8281-AA5566BF05C5Q39116600-B31131B7-860A-459D-8C8F-B862D4FA04C6Q39433453-F06E2238-9D86-4256-B8B2-2A0F77C3B930Q39534421-BCD271A3-3FA2-4670-A71A-49113438044BQ39986329-5E2161B0-F6CA-4E16-B45F-0DD21D9EA39DQ40036168-89EA7AC6-9E62-48EA-9DC5-20C9D1AF2710Q41869410-914CBCA2-79E7-4D1D-A093-9D9D7C7B12AEQ41892380-66F5745B-F1CA-4F8A-A606-5A76C917C9E1Q42396417-7CEF1816-ACF0-4194-A3A1-43F783D073F3Q42509995-887B2E36-E554-47B3-AA0C-B66F4A34E092Q46930050-033BE859-E2BA-435B-A12F-3C418FD218DCQ47290849-A40339CF-D7C5-4038-BF43-D697DD329815Q47604813-98F670C9-DE31-453A-ACD2-E493B91CEFA4Q51308775-15C25E29-3BAB-44D9-9FAB-32377B614DEBQ55029136-A2D9B1AF-F320-493E-890D-F89847B6FE13Q55167517-04AE47EA-FA5D-4BCF-BC1D-A0068DA3DDACQ57022679-16EC58AA-0113-4A55-82E5-6F29B93DB773Q58825364-BC4F9CFE-0AF2-4E41-99E0-F53253C4D12BQ61757404-F00DEBE3-8DD6-4301-8D9F-ECB96E6071BCQ64445656-55C9E76C-03E2-415E-92E2-8F19D19F1CF4Q83443991-2317CE5B-211F-437A-91DC-4AE32A52D619
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Darran P O'Connor
@ast
Darran P O'Connor
@en
Darran P O'Connor
@es
Darran P O'Connor
@nl
type
label
Darran P O'Connor
@ast
Darran P O'Connor
@en
Darran P O'Connor
@es
Darran P O'Connor
@nl
prefLabel
Darran P O'Connor
@ast
Darran P O'Connor
@en
Darran P O'Connor
@es
Darran P O'Connor
@nl
P108
P108
P1153
7401497062
P31
P496
0000-0002-8835-1547